Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma

被引：0
|
作者：
Lokhorst, Henk M.
Plesner, Torben
Gimsing, Peter
Nahi, Hareth
Minnema, Monique
Lassen, Ulrik Niels
Krejcik, Jakub
Laubach, Jacob
Lisby, Steen
Basse, Linda
Richardson, Paul Gerard Guy
机构：
[1] UMC Utrecht, Utrecht, Netherlands
[2] Vejle Hosp, Vejle, Denmark
[3] Copenhagen Univ Hosp, Copenhagen, Denmark
[4] Karolinska Univ, Sjukhuset Huddinge, Huddinge, Sweden
[5] Rigshosp, DK-2100 Copenhagen, Denmark
[6] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA
[7] Genmab AS, Copenhagen, Denmark
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8512
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study
    Shinsuke Iida
    Kenshi Suzuki
    Shigeru Kusumoto
    Masaki Ri
    Nobuhiro Tsukada
    Yu Abe
    Masayuki Aoki
    Mitsuo Inagaki
    International Journal of Hematology, 2017, 106 : 541 - 551
  • [2] Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study
    Iida, Shinsuke
    Suzuki, Kenshi
    Kusumoto, Shigeru
    Ri, Masaki
    Tsukada, Nobuhiro
    Abe, Yu
    Aoki, Masayuki
    Inagaki, Mitsuo
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 106 (04) : 541 - 551
  • [3] Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003)
    Hongmei Jing
    Li Yang
    Junyuan Qi
    Lugui Qiu
    Chengcheng Fu
    Junmin Li
    Min Yang
    Ming Qi
    Ni Fan
    Jia Ji
    Jiajia Lu
    Yunan Li
    Jie Jin
    Annals of Hematology, 2022, 101 : 2679 - 2690
  • [4] Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003)
    Jing, Hongmei
    Yang, Li
    Qi, Junyuan
    Qiu, Lugui
    Fu, Chengcheng
    Li, Junmin
    Yang, Min
    Qi, Ming
    Fan, Ni
    Ji, Jia
    Lu, Jiajia
    Li, Yunan
    Jin, Jie
    ANNALS OF HEMATOLOGY, 2022, 101 (12) : 2679 - 2690
  • [5] A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma
    Hansson, Markus
    Gimsing, Peter
    Badros, Ashraf
    Niskanen, Titti Martinsson
    Nahi, Hareth
    Offner, Fritz
    Salomo, Morten
    Sonesson, Elisabeth
    Mau-Sorensen, Morten
    Stenberg, Yvonne
    Sundberg, Annika
    Teige, Ingrid
    Van Droogenbroeck, Jan
    Wichert, Stina
    Zangari, Maurizio
    Frendeus, Bjorn
    Korsgren, Magnus
    Poelman, Martine
    Tricot, Guido
    CLINICAL CANCER RESEARCH, 2015, 21 (12) : 2730 - 2736
  • [6] A phase I, dose-escalation study of oral PIM447 in Japanese patients with relapsed and/or refractory multiple myeloma
    Iida, Shinsuke
    Sunami, Kazutaka
    Minami, Hironobu
    Hatake, Kiyohiko
    Sekiguchi, Risa
    Natsume, Kazuto
    Ishikawa, Norifumi
    Rinne, Mikael
    Taniwaki, Masafumi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (06) : 797 - 806
  • [7] Phase I dose-escalation study of cyclophosphamide combined with bortezomib and dexamethasone in Japanese patients with relapsed and/or refractory multiple myeloma
    Sugiura, Isamu
    Terabe, Satomi
    Kinoshita, Tomohiro
    Yamamoto, Kazuhito
    Sawa, Masashi
    Ozawa, Yukiyasu
    Atsuta, Yoshiko
    Suzuki, Ritsuro
    Shimizu, Kazuyuki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 102 (04) : 434 - 440
  • [8] Phase I dose-escalation study of cyclophosphamide combined with bortezomib and dexamethasone in Japanese patients with relapsed and/or refractory multiple myeloma
    Isamu Sugiura
    Satomi Terabe
    Tomohiro Kinoshita
    Kazuhito Yamamoto
    Masashi Sawa
    Yukiyasu Ozawa
    Yoshiko Atsuta
    Ritsuro Suzuki
    Kazuyuki Shimizu
    International Journal of Hematology, 2015, 102 : 434 - 440
  • [9] A phase I, dose-escalation study of oral PIM447 in Japanese patients with relapsed and/or refractory multiple myeloma
    Shinsuke Iida
    Kazutaka Sunami
    Hironobu Minami
    Kiyohiko Hatake
    Risa Sekiguchi
    Kazuto Natsume
    Norifumi Ishikawa
    Mikael Rinne
    Masafumi Taniwaki
    International Journal of Hematology, 2021, 113 : 797 - 806
  • [10] Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
    Richardson, Paul G.
    Weller, Edie
    Jagannath, Sundar
    Avigan, David E.
    Alsina, Melissa
    Schlossman, Robert L.
    Mazumder, Amitabha
    Munshi, Nikhil C.
    Ghobrial, Irene M.
    Doss, Deborah
    Warren, Diane L.
    Lunde, Laura E.
    McKenney, Mary
    Delaney, Carol
    Mitsiades, Constantine S.
    Hideshima, Teru
    Dalton, William
    Knight, Robert
    Esseltine, Dixie-Lee
    Anderson, Kenneth C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) : 5713 - 5719
12345